In: Diseases of Swine
Neuroprotection: extrapolating from neurologic disease to the eye
Chiarugi, A., Dlle, C., Felici, R
In the News Antibody-drug conjugate achieves high response rates as frontline treatment in aggressive, rare blood cancer Leukemia specialists: How advances in measurable residual disease (MRD) are improving cancer care ASCO: New antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer ASH: Novel combination therapy significantly reduces spleen volume in patients with myelofibrosis Understanding the types of leukemia Reflections on caring for cancer patients during the COVID-19 pandemic New blastic plasmacytoid dendritic cell neoplasm (BPDCN) treatment improves outlook for many patients ARCHIVED: Investigational drug shows promising results in Phase II study of aggressive, often fatal blood disorder with no approved therapies Present Title & Affiliation Primary Appointment Professor, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX Dual/Joint/Adjunct Appointment Professor, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX Research Interests Patients with AML and BPDCN: CD123-targeted clinical trial with SL-401
L-Carnitine 500mg L-Carnitine 500mg LOCAL DELIVERY WITHIN SINGAPORE For orders above $50, we offer free local delivery within Singapore
